Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1 by Boulter, Etienne et al.
Regulation of RhoGTPase crosstalk, degradation and activity by 
RhoGDI1
Etienne Boulter1,3,5, Rafael Garcia-Mata1,5, Christophe Guilluy1, Adi Dubash1,4, Guendalina 
Rossi1, Patrick J. Brennwald1, and Keith Burridge1,2,6
1Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill, 
Chapel Hill, North Carolina 27599, USA.
2Lineberger Comprehensive Cancer Center and UNC McAllister Heart Institute, University of 
North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
Abstract
At steady state, most Rho GTPases are bound in the cytosol to Rho Guanine nucleotide 
Dissociation Inhibitors (RhoGDI) 1. RhoGDIs have generally been considered to passively hold 
Rho proteins in an inactive state within the cytoplasm. Here we describe an evolutionarily 
conserved mechanism by which RhoGDI1 controls the homeostasis of Rho proteins in eukaryotic 
cells. We found that depletion of RhoGDI1 promotes misfolding and degradation of the cytosolic 
geranylgeranylated pool of Rho GTPases while unexpectedly activating the remaining membrane-
bound fraction. Since RhoGDI1 levels are limiting, and Rho proteins compete for binding to 
RhoGDI1, overexpression of an exogenous Rho GTPase displaces endogenous Rho proteins 
bound to RhoGDI1, inducing their degradation and inactivation. These results raise important 
questions about the conclusions drawn from studies that manipulate Rho protein levels. In many 
cases the response observed may arise not simply from the overexpression per se, but from 
additional effects on the levels and activity of other Rho GTPases due to competition for binding 
to RhoGDI1, and may require a re-evaluation of previously published studies that rely exclusively 
on these techniques.
The RhoGDI family has been generally relegated to a secondary role in the regulation of 
Rho GTPases1. To explore the function of RhoGDI1, we analyzed the effect of depleting 
RhoGDI1 in mammalian cells. Upon RhoGDI1 depletion by siRNA, the protein levels of the 
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major Rho GTPases, including RhoA, RhoC, Rac1 and Cdc42 were dramatically decreased 
(Fig.1a). This occurred for multiple cell types, including HeLa, fibroblasts, breast epithelial, 
melanoma and endothelial cells (Fig.1a, Supplementary Fig.S1a–d). RhoB, which does not 
bind RhoGDI1, was unaffected by RhoGDI1 silencing (Fig.1a and Supplementary 
Fig.S2a,b). The mRNA levels of RhoA, Rac1 and Cdc42 remained constant suggesting that 
post-transcriptional mechanisms account for the decrease in Rho proteins (Fig.1b). Indeed, 
proteasomal inhibitors such as LLnL, but not calpain or cathepsin inhibitors, partially 
rescued Rho proteins from degradation suggesting without RhoGDI1, the GTPases are being 
cleared by the proteasome (Fig.1c and data not shown). Rescue from degradation was 
achieved by expressing a siRNA-resistant RhoGDI1 (Fig.1d and Supplementary Fig. S2d). 
A second independent RhoGDI1 siRNA generated similar effects (data not shown). 
Interaction between the Rho-GTPases and RhoGDI is essential to prevent GTPase 
degradation since siRNA-resistant mutants that cannot bind Rho GTPases2 failed to rescue 
the effects of RhoGDI1 depletion (Fig.1d). Overexpression of wildtype RhoGDI1 but not 
the GTPase binding-deficient mutant increased the total level of RhoA and Rac1 (Fig.1e). 
These results indicate that RhoGDI1 stabilizes Rho proteins, protecting them from 
degradation.
Even though RhoA, Rac1 and Cdc42 levels were drastically reduced after RhoGDI1 
depletion, the amount of active Rho proteins was either significantly increased (Rac1 and 
Cdc42) or unchanged (RhoA) (Fig.1f), which indicates that a much larger fraction of the 
remaining pool of GTPase is in the active GTP-bound state. While the activity increases by 
up to 2 fold, the ratio between active and total GTPase increases by up to 10 fold due to the 
decrease in GTPase protein level (Fig.1g). At steady state, the active GTPase represented 
1% of total RhoA while in the absence of RhoGDI1, it peaked at 10% (Fig.1f and g). After 
RhoGDI1 depletion most RhoA is in the membrane fraction, suggesting that most of the 
degraded protein derives from the cytosolic pool (Fig.1h) and that the active fraction is 
associated with membranes. In contrast when an individual GTPase is silenced, both the 
protein levels and the activity are proportionally reduced (Fig.1i). These results highlight the 
importance of GDI proteins in regulating both the protein level and activation state of Rho 
GTPases. RhoGDI depletion in other cell types (WM2664 and HUVECs) caused similar 
decreases in Rho protein levels (Supplementary Fig. S1a–d), while the activity of the 
remaining fraction was either elevated or unchanged (Fig. 2d and Fig.S1d). Studying 
HUVECs, Gorovoy et al. also found that RhoGDI knockdown promoted RhoA activation, 
although Rho protein expression was not decreased as much as observed here, probably 
because the knockdown was only allowed to proceed for 30 hours3. More complete 
RhoGDI1 knockdown and Rho GTPase degradation is achieved at longer time intervals 
(Supplementary Fig. S1e).
To determine whether this aspect of RhoGDI function is evolutionarily conserved, we 
analyzed the effect of deleting the single RhoGDI gene in S. cerevisiae (RDI1). Strikingly, 
the loss of Rdi1 protein also resulted in degradation of Cdc42 and Rho1 (RhoA ortholog) 
while maintaining high levels of activation (Fig.1j). When analyzed by 
immunofluorescence, both Cdc42 and Rho1 had an increase in protein polarized in the bud, 
which has previously been correlated with localization of the activated forms of these 
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proteins4, 5 (Fig.1k and l). The increase in polarized bud staining is striking given the 
overall reduction in Rho1 and Cdc42 protein levels in rdi1Δ strains.
RhoGDI1 knockout mice are viable but display progressive kidney defects leading 
ultimately to death6. Interestingly, those defects have been attributed to increased Rac1 
activation and the kidneys display reduced levels of Rho GTPases7. Renal mesangial cells 
from RhoGDI knockout mice display altered growth and survival8. However, RhoGDI1 null 
mouse fibroblasts showed no defects in the reorganization of the actin cytoskeleton upon 
stimulation with growth factors, or in cell migration measured in a wound healing assay6. 
Yeast cells lacking rdi1, have a very minor phenotype9. Surprised by the relatively mild 
phenotype in spite of the marked change in Rho protein levels and activity, we have 
explored this further. Consistent with previous work, the rate of wound closure was 
unaffected when RhoGDI1 was knocked down in HeLa cells (Fig.2a). However, the 
migration velocity of highly motile melanoma cells was significantly decreased upon 
RhoGDI knockdown, both in a wound healing assay (Fig.2b) and when single cell migration 
was analyzed (Fig.2c, f, g and Supplementary information movie 1). This decrease in 
migration speed was unanticipated, given that Rac1 activity was increased (Fig.2d). 
However, RhoA activity also increased proportionally and may counteract the effects of 
high Rac1 activity (Fig.2d).
Although RhoGDI1 knockdown affected cell migration, we were surprised by the 
unexpectedly mild phenotype given the striking level of Rho protein activation following 
RhoGDI1 depletion. Examining whether RhoGDI2 might compensate for the loss of 
RhoGDI1 we found that, in cells expressing RhoGDI2 (HeLa and HUVEC), RhoGDI2 
levels did not vary after RhoGDI1 KD (Supplementary Fig.S1d and Fig. S3c). In WM2664 
and gingival fibroblasts the expression of RhoGDI2 was undetectable and unaffected by 
RhoGDI1 silencing (Supplementary Fig.S3c). In HeLa cells, silencing GDI-1 and GDI-2 
showed no effect on wound closure speed (Supplementary Figure S3a), suggesting the lack 
of phenotype is not due to a GDI-2 compensation effect.
We hypothesized that upon RhoGDI1 depletion, Rho proteins may fail to properly localize 
to the plasma membrane (PM) and may remain in the Endoplasmic Reticulum (ER), where 
the final steps in Rho GTPase maturation occur on the cytoplasmic face of the ER. Here they 
are postranslationally processed after being prenylated in the cytosol 10. Subcellular 
fractionation experiments showed that, in control cells RhoA, Rac1 and Cdc42 display a 
biphasic distribution occurring in both the PM and ER fractions (Fig.2h,i). However, 
following RhoGDI1 depletion the amount of Rho GTPases found associated with the PM 
was greatly reduced with the majority of the remaining GTPases cofractionating with the ER 
(Fig.2h,i). These results reveal that, without RhoGDI1, Rho proteins that are not degraded 
are not properly delivered to the PM. Instead, they accumulate at the ER suggesting that one 
function of RhoGDI1 is to shuttle Rho GTPases from the ER to their site of action at the 
PM. Supporting these results, we did not detect an increase in effector activation following 
GDI-1 KD, despite the high levels of active GTPases (Fig.2e). These results may explain the 
mild phenotype resulting from RhoGDI1 depletion in spite of high Rho protein activity.
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Rho proteins undergo ubiquitylation and degradation by the proteasome upon irreversible 
activation by the bacterial toxin CNF111. Since RhoGDI1 knockdown promoted a 
substantial activation of Rho proteins, we explored if degradation occured similarly, 
following activation. To inhibit activation of RhoA we either overexpressed the RhoA-
specific GAP, p190-RhoGAP, or incubated cells with C3-transferase, which inactivates 
RhoA, and then monitored its degradation following GDI1 silencing. Both treatments 
reduced RhoA activity to negligible amounts (Fig.3a,b). However, degradation of RhoA 
after GDI1 depletion still occurred, indicating that this is independent of RhoA activation 
(Fig.3a,b).
Our results suggest that binding to RhoGDI1 stabilizes and protects Rho GTPases from 
degradation, and that a GTPase that is not bound to a GDI protein or associated with the 
membrane is rapidly degraded. Most Rho proteins (RhoA, Rac1 and Cdc42) are 
posttranslationally modified at the C-terminus with a geranylgeranyl group12. General 
prenylation inhibitors from the statin family, such as lovastatin, or geranylgeranyl 
transferase specific inhibitors like GGTI2417 rescued the degradation of GTPases in the 
absence of GDI (Fig.3c, and data not shown). Similarly, cleavage of the geranylgeranylated 
C-terminal tail using the bacterial protease YopT13also restored RhoA levels, indicating that 
newly synthesized Rho proteins are prenylated and fully mature before being degraded and 
that removing the prenylation is sufficient to stabilize Rho GTPases (Fig.3d). GGTI2417 
treatment restores the cytosolic pool of RhoA in the absence of RhoGDI1, suggesting that a 
Rho GTPase can only exist in the cytosol if it is either bound to RhoGDI1 or not prenylated 
(Supplementary Fig. S4).
We speculated that, without the RhoGDI1 to protect the prenyl group, this exposed 
hydrophobic modification might disturb the correct folding of Rho proteins, targeting them 
to degradation. In cells, proper protein folding is ensured by molecular chaperones14. 
Proteins that cannot fold properly usually cluster in insoluble aggregates that are targeted for 
degradation14. We found that under physiological conditions, RhoA associates with the 
molecular chaperone Hsp70 (Fig.3e). In the absence of RhoGDI1, the levels of Hsp70 
increased in the cells indicative of a cellular stress but virtually no Hsp70 was bound to 
RhoA, suggesting that the remaining membrane-bound RhoA is properly folded and stable 
(Fig.3e). Indeed, Hsp70 bound mostly to cytosolic RhoA (Fig.3f). When we inhibited the 
proteasome in RhoGDI1-depleted cells, RhoA and Rac1 accumulated in a triton-insoluble 
fraction (data not shown). The amount of Hsp70 bound to cytosolic RhoA also increased, 
suggesting that the pool of free prenylated RhoA was misfolded or partially unfolded and 
recruited the protein quality control machinery (Fig.3f). These results suggest that 
prenylation contributes to the misfolding or unfolding of Rho proteins, resulting in their 
degradation if RhoGDI1 cannot accommodate the lipid moiety and if the molecular 
chaperones cannot fold them properly. Interestingly, although RhoA co-precipitates with 
both Hsp70 and RhoGDI1 (Fig.3e), immunoprecipitation of RhoGDI1 indicates that there 
are two mutually exclusive pools of RhoA associated with either Hsp70 or RhoGDI1 
(Supplementary Fig. S2a). Finally, inhibiting molecular chaperones with geldanamycin 
decreased RhoA levels in the presence or absence of RhoGDI1, arguing that molecular 
chaperones are required to help stabilize prenylated RhoA (Fig.3g).
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In mammalian cells, the level of RhoGDI1 is roughly equivalent to the total levels of RhoA, 
Rac1 and Cdc42 combined15. Therefore, a competitive balance exists between Rho proteins 
for binding to RhoGDI1 and any condition that alters the level of one GTPase should disrupt 
this balance and affect Rho protein homeostasis. Figure 4a shows that silencing RhoA 
results in decreased levels of RhoA and proportionally increased levels of Rac1 and Cdc42, 
indicating that reducing one GTPase generates free GDI that can be shared by the others. In 
contrast, overexpression of myc-tagged RhoA, Rac1 or Cdc42 displaced endogenous RhoA 
from RhoGDI1 (Fig.4b). Overexpression of a myctagged Cdc42 mutant (R66E) incapable of 
binding RhoGDI did not affect the level of endogenous RhoA (Fig.4c). The displacement of 
endogenous Rho proteins resulted in their degradation in a dose-dependent fashion (Fig.
4d,g,j). Strikingly, expression of constitutively active (Fig.4e,h,k) or dominant negative Rho 
proteins (Fig.4f,i,l) also displaced endogenous Rho proteins from RhoGDI1 and caused their 
degradation. The degradation of RhoA by overexpression of Cdc42 could be prevented by 
co-expression of RhoGDI1 (Fig.4m). Displacement of Rho proteins from RhoGDI1 by other 
Rho family members, including RhoA, Rac1 and Cdc42, resulted in their degradation and 
inactivation (Fig.4n,o,p). This degradation and inactivation did not occur if the 
overexpressed Rho protein was a mutant (RhoAR68E, Rac1R66E or Cdc42R66E) unable to 
bind RhoGDI1 (Fig.4n,o,p). The decrease in activity of Rho GTPases displaced from 
RhoGDI1 is similar to that observed when GTPases are silenced by RNAi (Fig.1i), and 
contrasts with the activation of Rho GTPases caused by RhoGDI1 depletion.
One might expect that depletion of RhoGDI1 and competitive displacement of Rho GTPases 
from RhoGDI1 would have the same effect on Rho protein activity, given that both result in 
degradation of Rho GTPases. However, in the case of overexpression of an exogenous Rho 
GTPase, RhoGDI1 is still present and over time will extract and inactivate the remaining 
endogenous GTPases from the membranes. Competitive displacement of endogenous Rho 
proteins from RhoGDI1 by overexpressed Rho GTPases will release the endogenous Rho 
proteins into the cytosol, followed by their degradation without the opportunity for 
activation. In contrast, during RhoGDI1 depletion, Rho proteins associated with membranes 
cannot be actively extracted by RhoGDI. These membrane-bound Rho GTPases are likely to 
become activated by membrane-bound GEFs. Since, RhoGDI1 can inhibit both the 
activation of the Rho GTPases, as well as GTP hydrolysis16, 17, depletion of RhoGDI1 
should relieve this inhibition, thereby promoting activation of the GTPases. In contrast, 
displacement of Rho proteins from GDI does not alter the cellular content of RhoGDI1, 
maintaining this inhibitory mechanism on endogenous GTPases. Indeed, we show that after 
RhoGDI1 depletion, the remaining RhoA that is not targeted for degradation is not bound to 
GDI (Fig.3e). Furthermore, our results demonstrate that depletion of RhoA by either direct 
silencing or by overexpressing an exogenous GTPase result in a decrease of both total and 
active RhoA, whereas RhoGDI silencing decreases RhoA levels but leaves RhoA activity 
high (Fig.1i and Fig.4o,p).
We have shown that RhoGDI1 regulates the stability of Rho GTPases within the cytosol, 
protecting them from degradation. Our results also reveal an unexpected crosstalk between 
Rho GTPases through competitive binding to RhoGDI1, illustrated schematically in Figure 
5. Rather little is known about changes in expression levels of RhoGDI1 or Rho GTPases 
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during development and disease, although situations have been described in which the 
expression of a Rho family member occurs, such as the increase of RhoC in metastasis18. In 
preliminary work, we have found that with different breast cancer cell lines the expression 
of RhoGDI1 correlates with their invasiveness, as well as with the level and activity of 
RhoA and Rac1 (Supplementary Fig. S5). However, in situations where the level of RhoGDI 
stays constant, our results predict that not only overexpressing one GTPase will displace the 
others from RhoGDI and target them for degradation but it will also affect their activity. 
One situation where extreme changes occur is in the experimental expression of wildtype or 
mutant Rho GTPases, which have been the standard tools to study Rho protein functions in 
different pathways. In many cases, the conclusions drawn from these studies may arise not 
only from the activity of the overexpressed Rho protein but also from the unanticipated 




All chemicals were purchased from Axxora (San Diego, CA, USA) unless mentioned. Cell 
permeable C3 toxin was from Cytoskeleton (Denver, CO, USA). The geranylgeranyl 
transferase inhibitor GGTI2417 was a gift from A. Cox (Department of Radiation Oncology, 
University of North Carolina, Chapel Hill, NC, USA).
Cell culture
HeLa and 293FT cells were grown in low glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. 
Gingival Fibroblasts (gift from Dr. Carol Otey, UNC-Chapel Hill) were grown in MEM 
alpha (Invitrogen) supplemented with 15% FBS (Sigma). WM2664 cells (gift from Dr. Jim 
Bear, UNC-Chapel Hill) were grown in DMEM (Invitrogen) supplemented with 10% FBS 
(Sigma). HUVECs were grown in EGM-2 (Clonetics, San Diego, CA, USA) until passage 4.
Yeast Culture and Immunofluorescence
Standard methods for yeast growth and cell permeabilization were as described in Guthrie 
and Fink 19. Immunofluorescence staining against Cdc42 and Rho1 was as described 
previously 20. The intensity of fluorescence associated with polarized Cdc42/Rho1 was 
measured in budded cells using Metamorph software using at least 20 cells of each strain.
Antibodies
The mouse monoclonal anti-RhoA antibody (26C4), the rabbit polyclonal anti-RhoB (119), 
anti-Rac2 (C11) and anti-RhoGDI1 (A20) antibodies, and the goat polyclonal anti-RhoC 
antibody (K12) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The mouse 
monoclonal anti-Rac1 (23A8) and anti-actin (C4) antibodies were from Millipore (Billerica, 
MA, USA). The mouse monoclonal anti-Cdc42 antibody was from BD Biosciences (San 
Jose, CA, USA). The mouse monoclonal anti-transferrin receptor, anti-tubulin and anti-PDI 
antibodies were from Sigma-Aldrich (St Louis, MO, USA). The mouse monoclonal anti-HA 
antibody (clone 16B12) was from Covance (Princeton, NJ, USA). The mouse monoclonal 
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anit-RhoGDI2 antibody was from BD Pharmingen (BD Bioscience, San Jose, CA, USA). 
The mouse monoclonal anti-myc antibody (clone 9E10) was a gift from Dr. Thomas Samson 
(UNC, Chapel Hill, USA). The mouse monoclonal anti-Hsp70 and anti-Hsp90 antibodies 
were gifts from Dr. Doug Cyr (UNC, Chapel Hill, USA). Affinity purified antibodies against 
yeast Cdc42 were previously described 20, Monoclonal antibody against yeast Rho1 
(UNC3-106.5.1) was isolated in collaboration with the UNC Immunology Core Facility.
DNA constructs, RNA interference, siRNAs and siRNA transfection
The wild type and mutant myc-tagged RhoA, Rac1 and Cdc42 eukaryotic expression 
constructs were previously described 21, 22. The Cdc42 R66E, RhoGDI1 rescue wt, D45A, 
D185A and D45/185A mutants were generated by site-directed mutagenesis using the 
Quickchange II XL Site-Directed Mutagenesis kit (Stratagene). The RhoGDI1 rescue 
constructs were generated by introducing silent mutations in the sequence targeted by the 
siRNA duplex. The pCMV-HA-p190 RhoGAP mammalian expression construct was 
described previously 23. The pGEX-YopT prokaryotic expression construct and the pCMV-
HA-RhoGDI1 mammalian expression construct were gifts from S.Ellerbroek (Wartburg 
College, Waverly, IA, USA). YopT cDNA was subcloned by PCR into the pPTuner IRES2 
vector of the ProteoTuner system (Clontech, Mountain View, CA, USA). The pAd-EmGFP-
RhoA miR shRNA construct was previously described 24. Short interfering RNAs (siRNAs) 
were designed using the BIOPREDsi algorithm at www.biopredsi.org 25. SiRNAs were 
purchased from the UNC Nucleic Acid Core Facility/Sigma-Genosys (Sigma-Aldrich, St 
Louis, MO, USA). The following siRNAs were used in this study (guide strand only): 
ARHGDIA#1/RhoGDI1#1 UCAAUCUUGACGCCUUUCCTT, negative control 
UCACUCGUGCCGCAUUUCCTT. SiRNAs were transfected using a modified calcium 
phosphate protocol as described previously 26.
RT-PCR
Total RNA was purified from HeLa cells using Trizol (Invitrogen, CA, USA) and was 
treated with DNAse I (NEB, Ipswich, MA, USA). Reverse transcription was carried out 
using the iScript cDNA Synthesis kit (Biorad, Hercules, CA, USA) on 1 µg of total RNA. 
PCR was performed on equal amounts of cDNA using the Taq PCR Master Mix kit (Qiagen, 
Valencia, CA, USA) and the following sets of oligonucleotides: RhoGDI1 
GGAGAGCTTCAAGAAGCAGT and TCAGTCCTTCCAGTCCTTCTT, RhoA, 
ATGGCTGCCATCCGGAAG and TCACAAGACAAGGCACCCAG, Rac1 
ATGCAGGCCATCAAGTGTGT and TTACAACAGCAGGCATTTTCTCT, Cdc42 
ATGCAGACAATTAAGTGTGTTGTT and TCATAGCAGCACACACCTGC, and β2 
microglobulin CTCGCGCTACTCTCTCTTTCTGG and 
GCTTACATCTCTCAATCCCACTTAA.
GST-RBD/PBD pull-down
Activation of respectively RhoA or Rac1/Cdc42 was measured in a GST-RBD or GST-PBD 
pull-down assay as previously described 27, 28. Briefly, cells were lysed in 25 mM Hepes 
pH 7.3, 150 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100, 4% Glycerol, 10 mM NaF, 5 mM 
DTT and protease inhibitors for 10 minutes at 4°C. Triton-X-100 insoluble material was 
removed by centrifugation for 10 minutes at 9500 g and the lysates were incubated with 50 
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µg of immobilized GST-RBD or GST-PBD for 40 minutes at 4°C, to measure respectively 
RhoA or Rac1/Cdc42 activity.
Subcellular fractionation
Cells were washed and incubated with ice-cold hypotonic lysis buffer (10 mM Hepes pH 
7.3, 1.5 mM MgCl2, 5 mM KCl, 1 mM DTT and protease inhibitors) for 10 minutes. Cells 
were scraped and homogeneized with 20 strokes of Dounce homogenizer. Homogenates 
were centrifuged at 700 g for 3 minutes to pellet nuclei and intact cells. The supernatants 
were spun at 40,000 g for 30 minutes at 4°C and the pellets were gently washed once with 
hypotonic lysis buffer. Typically, 2 to 5% of the cytosolic fraction and 30 to 40% of the 
membrane fraction were analyzed by SDS-PAGE and Western blot. Alternatively, 
membranes were fractionated using an iodixanol (OptiPrep, Axis Shield) discontinuous 
gradient according to the manufacturer’s instructions. Briefly, the membrane pellets were 
resuspended thoroughly in homogeneization buffer (0.25 M sucrose, 20 mM Tris/HCl pH 
7.4, 25 mM KCl, 5 mM MgCl2) and layered on top of a 5% to 30% discontinuous iodixanol 
gradient. The samples were the centrifuged for 2 h at 100,000 g. Fractions were then 
collected and analyzed by western blot.
Immunoprecipitation
Cells were lysed in ice-cold lysis buffer (without DTT) as described in the GST pull-down 
section. Lysates were centrifuged at 10,000 rpm for 10 minutes. RhoGDI1 was 
immunoprecipitated with 2 µg of rabbit polyclonal anti-RhoGDI1 antibody for one hour. 
RhoA was immunoprecipitated with 0.4 µg of mouse monoclonal anti-RhoA antibody 
(26C4) overnight. Lysates were then incubated with protein A-sepharose beads for 45 
minutes and were washed 3 times with lysis buffer.
Single Cell Migration
WM2664 cells were transfected with CTRL siRNA or GDI-1 specific siRNA using siQuest 
transfection reagent (Mirus). The GDI-1 siRNA was mixed with 1:10 of a fluorescently 
labeled non-targeting siRNA to identify the transfected cell. In control experiments all cells 
were transfected with the fluorescent siRNA (not shown). 48h after transfection CTRL and 
GDI-1 KD cells were trypsinized, mixed 1:1 and plated in a glass bottom 35 mm dish 
(MatTek) coated with laminin (Sigma). Time-lapse images were acquired using a Nikon 
BioStation IM live-cell imaging microscope and analyzed using ImageJ (NIH). Images were 
captured every 5 min for a total of 2 h. Usually 20 different fields were captured in a single 
experiments (approx. 60 cells).
Wound Healing
HeLa cells transfected with CTRL siRNA or GDI-1 siRNA. After 48 h cells were 
trypsinized and plated in a 24 well plate. A scratch/wound was made using a pipette tip in 
each of the wells. The cells were then imaged at the indicated times using a Zeiss Axiovert 
200 M microscope equipped with a Hamamatsu ORCA-ERAG digital camera. The wound 
area was measured at each time point using Metamorph Software (Molecular Devices).
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Statistical differences between two groups of data were analysed with two-tailed unpaired 
Student's t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RhoGDI1depletion triggers both degradation and activation of Rho proteins in 
eukaryotic cells
(a) Lysates from control or RhoGDI1 siRNA transfected HeLa cells were resolved by SDS-
PAGE and analyzed by Western blotting. (b) Total RNAs were purified from control or 
RhoGDI1 siRNA transfected cells. RT-PCR was performed on DNAse I treated RNA using 
specific primers. RT-PCR products were resolved by agarose gel electrophoresis. (c) Lysates 
from control or RhoGDI1 siRNA transfected HeLa cells treated with LLnL for 8 hours were 
resolved by SDS-PAGE and analyzed by Western blotting. (d) HeLa cells were co-
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transfected with control or RhoGDI1 siRNA and HA-tagged RhoGDI1 RNAi resistant 
mutants. Cell lysates were resolved by SDS-PAGE and analyzed by Western blotting. All 
results are representative of at least 3 independent experiments. Note that the degradation of 
RhoA in RhoGDI1-depleted cells is rescued by expression of RhoGDI1 resistant to the 
siRNA, but not by RhoGDI1 mutants that do not bind Rho GTPases. (e) Lysates from HeLa 
cells transfected with HA-tagged wt RhoGDI1 or RhoGDI1 D45/185A were resolved by 
SDS-PAGE and analyzed by Western blotting. All siRNA experiments were analyzed at 72 
h after transfection. For overexpression experiments, cells were transfected with the 
indicated cDNA 48 h after siRNA transfection and incubated for an additional 24 h. (f) 
HeLa cells were transfected with control or RhoGDI1 siRNA for 72 h. Active Rho GTPases 
were pulled-down from cell lysates with GST-RBD or GST-PBD beads. Bound proteins and 
total cell lysates were resolved by SDS-PAGE and analyzed by Western blotting. (g) 
Quantitation of the activation of RhoA, Rac1 and Cdc42 in RhoGDI1-depleted cells (black 
bars) relative to control cells (white bars). * p=0.0108, p=0.0146 and p=0.0229 respectively 
for RhoA, Rac1 and Cdc42 in a two-tail unpaired student’s t test with error bars representing 
standard error of the mean (s.e.m.) from three independent experiments. (h) Control or 
RhoGDI1 siRNA transfected cells were fractionated into cytosol and membrane fractions, 
resolved by SDS-PAGE and analyzed by Western blotting. TfR stands for transferrin 
receptor. (i) HeLa cells were infected with a RhoA miR shRNA-expressing adenovirus or 
transfected with RhoGDI1 siRNA for 72 h. Active RhoA was pulled-down with GST-RBD. 
Total cell lysates and GST-RBD bound proteins were resolved by SDS-PAGE and analyzed 
by Western blotting. (j) Active Rho GTPases from wild-type or Rdi1d yeast strains were 
pulled-down with GTP-RBD or GST-PBD beads. Bound proteins and total cell lysates were 
resolved by SDS-PAGE and analyzed by Western blotting. The Sso protein is used as 
loading control. (k) Immunofluorescence staining of Cdc42 and Rho1 in control wild-type 
(RDI1) and rdi1Δ strains. Scale bar is 8µm. (l) Quantitation of the intensity of polarized bud 
staining in control wild-type (RDI1) and rdi1Δ strains. Data were analyzed by two-tail 
student’s t test (p < 0.005) with error bars representing standard deviation from three 
experiments.
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Figure 2. RhoGDI1 depletion impairs cell migration
(a) Time-course analysis of closure of a wound generated on a confluent monolayer of 
control or RhoGDI1 siRNA transfected HeLa cells. The graph depicts the wound area with 
error bars representing standard deviation (n=10). (b) Time-course analysis of closure of a 
wound generated on a confluent monolayer of control or RhoGDI1 siRNA transfected 
WM2664 melanoma cells. The graph depicts the wound area with error bars representing 
standard deviation (n=6). (c) Analysis of the velocity of control or RhoGDI1 siRNA 
transfected WM2664 melanoma cells. Data were analyzed by two-tailed unpaired student’s t 
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test (p= 1.72×10−14) with error bars representing standard error of the mean (s.e.m.) from 
respectively n=28 and n=56 cells. The average speed of control and RhoGDI1 knock-down 
cells was 12.74 µm/min and 5.64 µm/min respectively. (d) WM2664 melanoma cells were 
transfected with control or RhoGDI1 siRNA for 72h. Active Rac1 and active RhoA were 
pulled-down from cell lysates with GST-PBD or GST-RBD beads respectively. Bound 
proteins and total cell lysates were resolved by SDS-PAGE and analyzed by Western 
blotting. (e) Cell lysates of control or RhoGDI1 siRNA transfected HeLa cells were resolved 
by SDS-PAGE and analyzed by Western blotting. Notice that Rho protein effectors are not 
activated despite the strong activation of RhoA and Rac. (f) Images extracted from 
supplementary information movie 1 depicting one WM2664 melanoma cell transfected with 
fluorescently labeled RhoGDI1 siRNA (red arrowhead) and two WM2664 cells transfected 
with unlabelled control siRNA (white and black arrowheads) migrating over time. Panel on 
right shows an image taken at t0 used to identify the cell transfected with the fluorescently 
labelled siRNA. Scale bar is 40 µm. (g) Representative XY migration tracks of control (left) 
or RhoGDI1 (right) siRNA transfected WM2664 melanoma cells. The positions of the cells 
were recorded every 5 minutes over a period of 2 hours (n=10). (h) HeLa cells transfected 
with control or RhoGDI1 siRNA for 72 h were fractionated into cytosolic or membrane 
fractions. Membrane fractions were further separated into plasma membrane (PM) and ER 
membrane (ER) by centrifugation on an iodixanol density gradient. Each fraction was 
analyzed by SDS-PAGE and Western blotting. (i) Densitometric analysis of the relative 
intensity of RhoA, Rac1 and Cdc42 bands in each fraction. Notice that upon RhoGDI1 
silencing, the GTPases essentially disappear from the plasma membrane fractions.
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Figure 3. Rho family GTPase degradation following RhoGDI1 depletion does not require 
activation of the Rho protein, but depends upon their geranylgeranylation and involves the 
molecular chaperone machinery
(a) HeLa cells were co-transfected with control or RhoGDI1 siRNA and p190RhoGAP 
cDNA. Active Rho GTPases were pulled-down from cell lysates with GST-RBD or GST-
PBD beads. Bound proteins and total cell lysates were resolved by SDS-PAGE and analyzed 
by Western blotting. (b) HeLa cells were transfected with control or RhoGDI1 siRNA and 
treated with cell permeable C3 toxin. Active Rho GTPases were pulled-down from cell 
lysates with GST-RBD or GST-PBD beads. Bound proteins and total cell lysates were 
resolved by SDS-PAGE and analyzed by Western blotting. (c) HeLa cells were transfected 
with control or RhoGDI1 siRNA and treated with the geranylgeranyl transferase inhibitor 
GGTI 2417. Cell lysates were resolved by SDS-PAGE and analyzed by Western blotting. 
(d) HeLa cells were co-transfected with control or RhoGDI1 siRNA and a cDNA encoding 
the bacterial protease YopT. Cell lysates were resolved by SDS-PAGE and analyzed by 
Western blotting. (e) HeLa cells were transfected with control or RhoGDI siRNA and RhoA 
was immunoprecipitated from cell lysates. Immunoprecipitated proteins were resolved by 
SDS-PAGE and analyzed by Western blotting. (f) HeLa cells transfected with control or 
RhoGDI1 siRNA, with or without the proteasome inhibitor LLnL, were fractionated into 
cytosolic or membrane fractions and RhoA was immunoprecipitated from cytosolic and 
membrane fractions. To ensure that similar amounts of RhoA were immunoprecipitated, 
immunoprecipitations were performed with limiting amount of antibody and saturating 
amounts of cell lysate. Immunoprecipitated proteins and cell lysates were resolved by SDS-
PAGE and analyzed by Western blotting. (g) HeLa cells were transfected with control or 
RhoGDI1 siRNA and treated with geldanamycin for 12 hours. Cell lysates were resolved by 
SDS-PAGE and analyzed by Western blotting. All results are representative of at least 3 
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independent experiments. A short and long exposure of the RhoA blot is shown. All siRNA 
experiments were analyzed at 72 h after transfection. For overexpression experiments, cells 
were transfected with the indicated cDNA 48 h after siRNA transfection and incubated for 
an additional 24 h.
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Figure 4. Competitive interactions with RhoGDI1 regulate the levels and activities of Rho 
proteins
(a) HeLa cells were infected with a RhoA miR shRNA adenovirus for 72 h. Cell lysates 
were resolved by SDS-PAGE and analyzed by Western blotting. Note the increased levels of 
Rac1 and Cdc42 in cells from which RhoA has been depleted. (b) HeLa cells were 
transfected with myc-tagged Rho GTPases and endogenous RhoGDI1 was 
immunoprecipitated. Immunoprecipitated proteins and cell lysates were resolved by SDS-
PAGE and analyzed by Western blotting. HeLa cells (c and d) or HEK 293 cells (e, f, g, h, i, 
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j, k and l) were transfected with increasing amount of plasmid encoding for the indicated 
myc-tagged Rho GTPases. After 24 h, cell lysates were resolved by SDS-PAGE and 
analyzed by Western blotting. (m) HEK 293 cells were transfected with myc-tagged Cdc42 
expressing plasmid with or without HA-tagged RhoGDI1 expressing plasmid for 24 h. Cell 
lysates were resolved by SDS-PAGE and analyzed by Western blotting. (n, o, and p) HEK 
293 cells were transfected with 5µg of myc-tagged Rho GTPase expression plasmid as 
indicated. After 24 h, active RhoA or active Rac1 were pulled-down from cell lysates with 
GST-RBD or GST-PBD beads respectively. Bound proteins and total cell lysates were 
resolved by SDS-PAGE and analyzed by Western blotting. All results shown are 
representative of at least 3 independent experiments. Note that overexpression of one Rho 
family member decreases the expression and activity of the other Rho proteins.
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Figure 5. RhoGDI regulates Rho protein homeostasis
Newly synthesized RhoGTPases are geranylgeranylated and posttranslationally modified in 
the ER. After geranylgeranylation, Rho proteins associate directly with RhoGDI which 
sequesters them as a soluble prenylated forming the cytosol and protects them from 
degradation. Upon depletion of RhoGDI1 or overexpression of Rho proteins, endogenous 
RhoGTPases are released to the cytosol where they exist as short-lived unstable 
intermediates that are partially folded or misfolded (red arrows). These can bind to the 
chaperone complex or be targeted for degradation if they are unable to fold properly. In the 
absence of GDI, newly synthesized Rho proteins cannot be delivered to the plasma 
membrane and accumulate in the ER. At steady state, this unstable intermediate is not 
detected and RhoGTPases are for the most part either associated with cell membranes or 
bound to GDI, with only a small fraction associated with the chaperone system.
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Abbreviations used: ER, endoplasmic reticulum; PM, plasma membrane; GGTase, 
geranylgeranyl transferase; Rce1, prenyl-protein specific protease; lcmt, isoprenylcysteine 
carboxyl methyltransferase.
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